News

NEW FAQ on Corona virus: re-direct in on-going Horizon 2020 projects to help tackling the Covid-19 outbreak

Published on | 6 years ago

Programmes
ERC RI MSCA FET ICT NMBP SPACE SME Instrument Health Food Energy Transport Climate/Environment Societies Security Widening SwafS JRC EIC Pilot Batteries Circular Industries Horizon 2020 H2020 L+F

FAQ from the Commission:

Amendments should in principle not imply changes to the project that would call into question the award decision. However, due to the current situation, if re-orienting your project might contribute to tackling the Coronavirus crisis, this could be granted (via an amendment), upon request by beneficiaries (assessed case-by-case by the funding body).

Other FAQ's related to Corona can be found in the news items on NCP Flanders.be.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1899 articles available search in articles 

Testimonial

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.